Greater Cannabis Company, Inc.

GCANOTC:GCAND

Pharmaceutical Preparations·BALTIMORE, MD

Summary Financials

Revenue

$12,630

-73.7% YoY

FY 2022

Adj. EBITDA

—

Net Income

-$188,402

-1491.7% margin

FY 2024

EPS (Diluted)

$0.00

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$270,030

FY 2023

Total Debt

$171,437

FY 2024

Net Cash

$98,593

FY 2024

Enterprise Value

—

Debt / EBITDA

—

EV / EBITDA

—

Employees

—

Revenue

$12,630

-73.7% YoY

FY 2022

Adj. EBITDA

—

Net Income

-$188,402

-1491.7% margin

FY 2024

EPS (Diluted)

$0.00

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$270,030

FY 2023

Total Debt

$171,437

FY 2024

Net Cash

$98,593

FY 2024

Enterprise Value

—

Debt / EBITDA

—

EV / EBITDA

—

Employees

—